BioCardia (BCDA)
(Delayed Data from NSDQ)
$0.38 USD
+0.01 (2.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.39 +0.01 (3.56%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Income Statements
Fiscal Year end for BioCardia, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 1 | 0 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 12 | 13 | 14 | 16 | 15 |
Income After Depreciation & Amortization | -12 | -12 | -13 | -16 | -14 |
Non-Operating Income | 0 | 0 | 0 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | -12 | -13 | -15 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -12 | -12 | -13 | -15 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -12 | -12 | -13 | -15 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -12 | -12 | -13 | -15 | -14 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -12 | -12 | -13 | -16 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 21.18 | 17.72 | 16.92 | 10.12 | 5.64 |
Diluted EPS Before Non-Recurring Items | -0.55 | -0.67 | -0.75 | -1.48 | -2.61 |
Diluted Net EPS (GAAP) | -0.55 | -0.67 | -0.75 | -1.48 | -2.61 |
Fiscal Year end for BioCardia, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.01 | 0.36 | 0.04 | 0.06 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.01 | 0.36 | 0.04 | 0.06 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.10 | 2.95 | 3.49 | 3.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.09 | -2.59 | -3.45 | -3.51 |
Non-Operating Income | NA | 0.01 | 0.02 | 0.03 | 0.01 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.07 | -2.57 | -3.42 | -3.50 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.07 | -2.57 | -3.42 | -3.50 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.07 | -2.57 | -3.42 | -3.50 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 21.18 | 21.62 | 20.39 | 20.18 |
Diluted EPS Before Non-Recurring Items | NA | -0.09 | -0.12 | -0.17 | -0.17 |
Diluted Net EPS (GAAP) | NA | -0.09 | -0.12 | -0.17 | -0.17 |